A novel class of lipophilic quinazoline-based folic acid analogues: cytotoxic agents with a folate-independent locus

Three lipophilic quinazoline-based aminomethyl pyridine compounds, which differ only in the position of the nitrogen in their pyridine ring, are described. CB300179 (2-pyridine), CB300189 (4-pyridine) and CB30865 (3-pyridine) all inhibited isolated mammalian TS with IC50 values of 508, 250 and 156 n...

Ausführliche Beschreibung

Gespeichert in:

Bibliographische Detailangaben
Veröffentlicht in:	British journal of cancer Jg. 79; H. 11-12; S. 1692
Hauptverfasser:	Skelton, L A, Ormerod, M G, Titley, J, Kimbell, R, Brunton, L A, Jackman, A L
Format:	Journal Article
Sprache:	Englisch
Veröffentlicht:	England 01.04.1999
Schlagworte:	Animals Antineoplastic Agents - therapeutic use Cell Cycle - drug effects Cell Division - drug effects Cell Survival - drug effects Chemical Precipitation Colony-Forming Units Assay Cytoprotection DNA, Neoplasm - biosynthesis Folic Acid - pharmacology Humans Leukemia L1210 - drug therapy Leukemia L1210 - pathology Lipid Metabolism Mice Quinazolines - therapeutic use Solubility Tumor Cells, Cultured
ISSN:	0007-0920
Online-Zugang:	Weitere Angaben
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Abstract	Three lipophilic quinazoline-based aminomethyl pyridine compounds, which differ only in the position of the nitrogen in their pyridine ring, are described. CB300179 (2-pyridine), CB300189 (4-pyridine) and CB30865 (3-pyridine) all inhibited isolated mammalian TS with IC50 values of 508, 250 and 156 nM respectively. CB30865 was the most potent growth inhibitory agent (IC50 values in the range 1-100 nM for several mouse and human cell types). CB300179 and CB300189 were active in the micromolar range. Against W1L2 cells, CB300179 and CB300189 demonstrated reduced potency in the presence of exogenous thymidine (dThd), and against a W1L2:C1 TS overproducing cell line. In contrast, CB30865 retained activity in these systems. Furthermore, combinations of precursors and end products of folate metabolism, e.g. dThd/hypoxanthine (HX) or leucovorin (LV), did not prevent activity. CB30865 did not interfere with the incorporation of tritiated dThd, uridine or leucine after 4 h. A cell line was raised with acquired resistance to CB30865 (W1L2:R865; > 200-fold), which was not cross-resistant to CB300179 or CB300189. In addition, W1L2:R865 cells were as sensitive as parental cells to agents from all the major chemotherapeutic drug classes. CB300179 and CB300189 induced an S phase accumulation (preventable by co-administration of dThd). No cell cycle redistribution was observed following exposure (4-48 h) to an equitoxic concentration of CB30865. In the NCI anticancer drug-discovery screen, CB30865 displayed a pattern of activity which was not consistent with known anti-tumour agents. These data suggest that CB30865 represents a class of potent potential anti-tumour agents with a novel mechanism of action.
AbstractList	Three lipophilic quinazoline-based aminomethyl pyridine compounds, which differ only in the position of the nitrogen in their pyridine ring, are described. CB300179 (2-pyridine), CB300189 (4-pyridine) and CB30865 (3-pyridine) all inhibited isolated mammalian TS with IC50 values of 508, 250 and 156 nM respectively. CB30865 was the most potent growth inhibitory agent (IC50 values in the range 1-100 nM for several mouse and human cell types). CB300179 and CB300189 were active in the micromolar range. Against W1L2 cells, CB300179 and CB300189 demonstrated reduced potency in the presence of exogenous thymidine (dThd), and against a W1L2:C1 TS overproducing cell line. In contrast, CB30865 retained activity in these systems. Furthermore, combinations of precursors and end products of folate metabolism, e.g. dThd/hypoxanthine (HX) or leucovorin (LV), did not prevent activity. CB30865 did not interfere with the incorporation of tritiated dThd, uridine or leucine after 4 h. A cell line was raised with acquired resistance to CB30865 (W1L2:R865; > 200-fold), which was not cross-resistant to CB300179 or CB300189. In addition, W1L2:R865 cells were as sensitive as parental cells to agents from all the major chemotherapeutic drug classes. CB300179 and CB300189 induced an S phase accumulation (preventable by co-administration of dThd). No cell cycle redistribution was observed following exposure (4-48 h) to an equitoxic concentration of CB30865. In the NCI anticancer drug-discovery screen, CB30865 displayed a pattern of activity which was not consistent with known anti-tumour agents. These data suggest that CB30865 represents a class of potent potential anti-tumour agents with a novel mechanism of action. Three lipophilic quinazoline-based aminomethyl pyridine compounds, which differ only in the position of the nitrogen in their pyridine ring, are described. CB300179 (2-pyridine), CB300189 (4-pyridine) and CB30865 (3-pyridine) all inhibited isolated mammalian TS with IC50 values of 508, 250 and 156 nM respectively. CB30865 was the most potent growth inhibitory agent (IC50 values in the range 1-100 nM for several mouse and human cell types). CB300179 and CB300189 were active in the micromolar range. Against W1L2 cells, CB300179 and CB300189 demonstrated reduced potency in the presence of exogenous thymidine (dThd), and against a W1L2:C1 TS overproducing cell line. In contrast, CB30865 retained activity in these systems. Furthermore, combinations of precursors and end products of folate metabolism, e.g. dThd/hypoxanthine (HX) or leucovorin (LV), did not prevent activity. CB30865 did not interfere with the incorporation of tritiated dThd, uridine or leucine after 4 h. A cell line was raised with acquired resistance to CB30865 (W1L2:R865; > 200-fold), which was not cross-resistant to CB300179 or CB300189. In addition, W1L2:R865 cells were as sensitive as parental cells to agents from all the major chemotherapeutic drug classes. CB300179 and CB300189 induced an S phase accumulation (preventable by co-administration of dThd). No cell cycle redistribution was observed following exposure (4-48 h) to an equitoxic concentration of CB30865. In the NCI anticancer drug-discovery screen, CB30865 displayed a pattern of activity which was not consistent with known anti-tumour agents. These data suggest that CB30865 represents a class of potent potential anti-tumour agents with a novel mechanism of action.Three lipophilic quinazoline-based aminomethyl pyridine compounds, which differ only in the position of the nitrogen in their pyridine ring, are described. CB300179 (2-pyridine), CB300189 (4-pyridine) and CB30865 (3-pyridine) all inhibited isolated mammalian TS with IC50 values of 508, 250 and 156 nM respectively. CB30865 was the most potent growth inhibitory agent (IC50 values in the range 1-100 nM for several mouse and human cell types). CB300179 and CB300189 were active in the micromolar range. Against W1L2 cells, CB300179 and CB300189 demonstrated reduced potency in the presence of exogenous thymidine (dThd), and against a W1L2:C1 TS overproducing cell line. In contrast, CB30865 retained activity in these systems. Furthermore, combinations of precursors and end products of folate metabolism, e.g. dThd/hypoxanthine (HX) or leucovorin (LV), did not prevent activity. CB30865 did not interfere with the incorporation of tritiated dThd, uridine or leucine after 4 h. A cell line was raised with acquired resistance to CB30865 (W1L2:R865; > 200-fold), which was not cross-resistant to CB300179 or CB300189. In addition, W1L2:R865 cells were as sensitive as parental cells to agents from all the major chemotherapeutic drug classes. CB300179 and CB300189 induced an S phase accumulation (preventable by co-administration of dThd). No cell cycle redistribution was observed following exposure (4-48 h) to an equitoxic concentration of CB30865. In the NCI anticancer drug-discovery screen, CB30865 displayed a pattern of activity which was not consistent with known anti-tumour agents. These data suggest that CB30865 represents a class of potent potential anti-tumour agents with a novel mechanism of action.
Author	Titley, J Skelton, L A Jackman, A L Kimbell, R Ormerod, M G Brunton, L A
Author_xml	– sequence: 1 givenname: L A surname: Skelton fullname: Skelton, L A organization: The CRC Centre for Cancer Therapeutics at The Institute of Cancer Research, Sutton, Surrey, UK – sequence: 2 givenname: M G surname: Ormerod fullname: Ormerod, M G – sequence: 3 givenname: J surname: Titley fullname: Titley, J – sequence: 4 givenname: R surname: Kimbell fullname: Kimbell, R – sequence: 5 givenname: L A surname: Brunton fullname: Brunton, L A – sequence: 6 givenname: A L surname: Jackman fullname: Jackman, A L
BackLink	https://www.ncbi.nlm.nih.gov/pubmed/10206279$$D View this record in MEDLINE/PubMed
BookMark	eNo1kL1PwzAQxT0U0Q9YGZEnthTHbu2Grar4kiqxwBxd7EvryrXT2gHKX08iyvJO995Pp9Mbk4EPHgm5ydk0Z2JxH3fTaqenUhaMKzYgI8aYyljB2ZCMY9x1a8EW6pIMc8aZ5KoYkbSkPnyio9pBjDTU1NkmNFvrrKaH1nr4Cc56zCqIaGgdeh-0NRQ8uLBpMT5QfUohhe8-2aBPkX7ZtKXQ05Aws95gg534RF3QbbwiFzW4iNfnOSEfT4_vq5ds_fb8ulquMz2bz1MmhVzwCgznINAUEoUxlYIapMEqX2jQbN4nHaYFy0Wta6OBc15IUamZ4hNy93e3OYZD92kq9zZqdA48hjaWspCFEKoHb89gW-3RlM3R7uF4Kv974r-71G1t
CitedBy_id	crossref_primary_10_1073_pnas_161272798 crossref_primary_10_1517_13543776_2012_665876 crossref_primary_10_1007_s00044_020_02533_4 crossref_primary_10_1021_jm101145b crossref_primary_10_4155_fmc_12_34 crossref_primary_10_1002_ardp_200700096 crossref_primary_10_1016_S0162_0134_99_00140_3 crossref_primary_10_1016_S0959_8049_99_00280_4 crossref_primary_10_1021_jm011081s crossref_primary_10_1016_S0925_4439_02_00084_4 crossref_primary_10_2174_1570180820666230310112000 crossref_primary_10_1016_j_chembiol_2010_05_008
ContentType	Journal Article
DBID	CGR CUY CVF ECM EIF NPM 7X8
DOI	10.1038/sj.bjc.6690270
DatabaseName	Medline MEDLINE MEDLINE (Ovid) MEDLINE MEDLINE PubMed MEDLINE - Academic
DatabaseTitle	MEDLINE Medline Complete MEDLINE with Full Text PubMed MEDLINE (Ovid) MEDLINE - Academic
DatabaseTitleList	MEDLINE MEDLINE - Academic
Database_xml	– sequence: 1 dbid: NPM name: PubMed url: http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed sourceTypes: Index Database – sequence: 2 dbid: 7X8 name: MEDLINE - Academic url: https://search.proquest.com/medline sourceTypes: Aggregation Database
DeliveryMethod	no_fulltext_linktorsrc
Discipline	Medicine
ExternalDocumentID	10206279
Genre	Research Support, Non-U.S. Gov't Journal Article
GroupedDBID	--- -Q- .55 .GJ 0R~ 23N 36B 39C 3V. 4.4 406 53G 5GY 5RE 6J9 70F 7RV 7X7 88E 8AO 8C1 8FI 8FJ 8R4 8R5 8WZ A6W AACDK AANZL AASML AATNV AAWTL AAYZH AAZLF ABAKF ABAWZ ABDBF ABLJU ABOCM ABUWG ABZZP ACAOD ACGFO ACGFS ACKTT ACPRK ACRQY ACUHS ACZOJ ADBBV ADFRT ADHDB AEFQL AEJRE AEMSY AENEX AEVLU AEXYK AFBBN AFKRA AFRAH AFSHS AGAYW AGHAI AGQEE AHMBA AHSBF AI. AIGIU AILAN AJRNO ALFFA ALMA_UNASSIGNED_HOLDINGS AMYLF AN0 AOIJS ASPBG AVWKF AXYYD AZFZN B0M BAWUL BBNVY BENPR BHPHI BKEYQ BKKNO BNQBC BPHCQ BVXVI CAG CCPQU CGR COF CS3 CUY CVF DIK DNIVK DPUIP DU5 E3Z EAD EAP EAS EBC EBD EBLON EBS ECM EE. EIF EIOEI EJD EMB EMK EMOBN EPL ESX EX3 F5P FDQFY FEDTE FERAY FIGPU FIZPM FRJ FSGXE FYUFA GX1 HCIFZ HMCUK HVGLF HYE HZ~ IH2 IWAJR J5H JSO JZLTJ KQ8 M1P M41 M7P NAO NAPCQ NPM NQJWS O9- OK1 P2P PQQKQ PROAC PSQYO Q2X RNT RNTTT ROL RPM SNX SNYQT SOHCF SOJ SRMVM SV3 SWTZT TAOOD TBHMF TDRGL TR2 TUS UDS UKHRP VH1 W2D WH7 WOW X7M Y6R ZGI ~02 ~8M 7X8 AAFWJ ABBRH ABDBE ABFSG ABRTQ ACSTC AEZWR AFDZB AFHIU AHWEU AIXLP ATHPR AYFIA
ID	FETCH-LOGICAL-c455t-63682bad22a3ed96e3ddb7afa6deb18cac05a3ed368c3013fcfdca222963b7472
IEDL.DBID	7X8
ISICitedReferencesCount	19
ISICitedReferencesURI	http://www.webofscience.com/api/gateway?GWVersion=2&SrcApp=Summon&SrcAuth=ProQuest&DestLinkType=CitingArticles&DestApp=WOS_CPL&KeyUT=000079314400010&url=https%3A%2F%2Fcvtisr.summon.serialssolutions.com%2F%23%21%2Fsearch%3Fho%3Df%26include.ft.matches%3Dt%26l%3Dnull%26q%3D
ISSN	0007-0920
IngestDate	Sun Sep 28 04:44:25 EDT 2025 Wed Feb 19 01:30:16 EST 2025
IsDoiOpenAccess	false
IsOpenAccess	true
IsPeerReviewed	true
IsScholarly	true
Issue	11-12
Language	English
LinkModel	DirectLink
MergedId	FETCHMERGED-LOGICAL-c455t-63682bad22a3ed96e3ddb7afa6deb18cac05a3ed368c3013fcfdca222963b7472
Notes	ObjectType-Article-1 SourceType-Scholarly Journals-1 ObjectType-Feature-2 content type line 23
OpenAccessLink	https://www.nature.com/articles/6690270.pdf
PMID	10206279
PQID	69693377
PQPubID	23479
ParticipantIDs	proquest_miscellaneous_69693377 pubmed_primary_10206279
PublicationCentury	1900
PublicationDate	1999-04-01
PublicationDateYYYYMMDD	1999-04-01
PublicationDate_xml	– month: 04 year: 1999 text: 1999-04-01 day: 01
PublicationDecade	1990
PublicationPlace	England
PublicationPlace_xml	– name: England
PublicationTitle	British journal of cancer
PublicationTitleAlternate	Br J Cancer
PublicationYear	1999
References	2386929 - Cancer Res. 1990 Sep 1;50(17):5212-8 7495479 - Anticancer Drug Des. 1995 Oct;10(7):555-72 8304186 - Adv Exp Med Biol. 1993;338:589-92 1737372 - Cancer Res. 1992 Mar 1;52(5):1137-43 2738938 - J Natl Cancer Inst. 1989 Jul 19;81(14):1088-92 2950953 - Biol Cell. 1986;58(2):135-8 2610126 - Adv Exp Med Biol. 1989;253B:383-8 2041050 - J Natl Cancer Inst. 1991 Jun 5;83(11):757-66 6720434 - Adv Exp Med Biol. 1984;165 Pt B:375-8 2938731 - Cancer Res. 1986 Jun;46(6):2810-5 8567390 - Jpn J Cancer Res. 1995 Nov;86(11):1014-8 3349474 - Cancer Res. 1988 Apr 15;48(8):2036-41 7660886 - Adv Exp Med Biol. 1994;370:185-8 3663476 - Br J Cancer. 1987 Sep;56(3):279-85 2936525 - Cancer Chemother Pharmacol. 1986;16(2):116-20 1596289 - Biochem Pharmacol. 1992 May 8;43(9):2029-31 9725559 - Cytometry. 1998 Sep 1;33(1):56-66 1741766 - Biochem Pharmacol. 1991 Oct 24;42(10):1885-95 7537518 - Br J Cancer. 1995 May;71(5):914-24 9815766 - Clin Cancer Res. 1997 Jun;3(6):911-21 6163527 - Cancer Res. 1981 Apr;41(4):1549-58 8958186 - Invest New Drugs. 1996;14(3):305-16
References_xml	– reference: 9815766 - Clin Cancer Res. 1997 Jun;3(6):911-21 – reference: 7495479 - Anticancer Drug Des. 1995 Oct;10(7):555-72 – reference: 2938731 - Cancer Res. 1986 Jun;46(6):2810-5 – reference: 1596289 - Biochem Pharmacol. 1992 May 8;43(9):2029-31 – reference: 6720434 - Adv Exp Med Biol. 1984;165 Pt B:375-8 – reference: 2041050 - J Natl Cancer Inst. 1991 Jun 5;83(11):757-66 – reference: 1737372 - Cancer Res. 1992 Mar 1;52(5):1137-43 – reference: 2936525 - Cancer Chemother Pharmacol. 1986;16(2):116-20 – reference: 6163527 - Cancer Res. 1981 Apr;41(4):1549-58 – reference: 8304186 - Adv Exp Med Biol. 1993;338:589-92 – reference: 7537518 - Br J Cancer. 1995 May;71(5):914-24 – reference: 8958186 - Invest New Drugs. 1996;14(3):305-16 – reference: 3663476 - Br J Cancer. 1987 Sep;56(3):279-85 – reference: 2738938 - J Natl Cancer Inst. 1989 Jul 19;81(14):1088-92 – reference: 7660886 - Adv Exp Med Biol. 1994;370:185-8 – reference: 2610126 - Adv Exp Med Biol. 1989;253B:383-8 – reference: 8567390 - Jpn J Cancer Res. 1995 Nov;86(11):1014-8 – reference: 1741766 - Biochem Pharmacol. 1991 Oct 24;42(10):1885-95 – reference: 2386929 - Cancer Res. 1990 Sep 1;50(17):5212-8 – reference: 9725559 - Cytometry. 1998 Sep 1;33(1):56-66 – reference: 2950953 - Biol Cell. 1986;58(2):135-8 – reference: 3349474 - Cancer Res. 1988 Apr 15;48(8):2036-41
SSID	ssj0009087
Score	1.6811891
Snippet	Three lipophilic quinazoline-based aminomethyl pyridine compounds, which differ only in the position of the nitrogen in their pyridine ring, are described....
SourceID	proquest pubmed
SourceType	Aggregation Database Index Database
StartPage	1692
SubjectTerms	Animals Antineoplastic Agents - therapeutic use Cell Cycle - drug effects Cell Division - drug effects Cell Survival - drug effects Chemical Precipitation Colony-Forming Units Assay Cytoprotection DNA, Neoplasm - biosynthesis Folic Acid - pharmacology Humans Leukemia L1210 - drug therapy Leukemia L1210 - pathology Lipid Metabolism Mice Quinazolines - therapeutic use Solubility Tumor Cells, Cultured
Title	A novel class of lipophilic quinazoline-based folic acid analogues: cytotoxic agents with a folate-independent locus
URI	https://www.ncbi.nlm.nih.gov/pubmed/10206279 https://www.proquest.com/docview/69693377
Volume	79
WOSCitedRecordID	wos000079314400010&url=https%3A%2F%2Fcvtisr.summon.serialssolutions.com%2F%23%21%2Fsearch%3Fho%3Df%26include.ft.matches%3Dt%26l%3Dnull%26q%3D
hasFullText
inHoldings	1
isFullTextHit
isPrint
link	http://cvtisr.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwpV1LS8QwEA7rA_Hi-_3KwWu0Nm3aiCAiLl522YPC3pZkkkJF2tV2Rf31zmy3ehIPXnpJAiWdznwzk3wfY6dSJc7oi1gAaEsJSiwwClrhwGF4D6T2Np2KTST9fjoc6kGHXbV3YehYZesTp47alUA18nOlFebeSXI9fhGkGUW91ZmAxhxbkAhkyKaT4Q9XuA7ShjGTinE6DFrKRpmeV09n9gnOFKaGYRL8Di6nQaa7-r_XW2MrM3DJbxprWGcdX2ywpd6sfb7J6htelG_-mQNhZl5m_Dkfl2OqqQB_meSF-SQNHy8otjmeEWcwN5A7boqmyFNdcvioy7p8pxG6llVxKuVyQ7MRt4r8W1e35hgoJ9UWe-zePdzei5nsgoAojmuhpEpDa1wYGumdVl46ZxOTGeXQsadgIIhpBKcBugeZQebAkC64khazk3CbzRdl4XcZj3C9RC8BUSAjY6xRCagIIaj1-sKnZo-dtLs5QrOmXoUpfDmpRu1-7rGd5oOMxg37xggREVEr6_0_1x6w5YZkgc7ZHLKFDH9of8QW4a3Oq9fjqbXgsz_ofQHoQs0x
linkProvider	ProQuest
openUrl	ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=A+novel+class+of+lipophilic+quinazoline-based+folic+acid+analogues%3A+cytotoxic+agents+with+a+folate-independent+locus&rft.jtitle=British+journal+of+cancer&rft.au=Skelton%2C+L+A&rft.au=Ormerod%2C+M+G&rft.au=Titley%2C+J&rft.au=Kimbell%2C+R&rft.date=1999-04-01&rft.issn=0007-0920&rft.volume=79&rft.issue=11-12&rft.spage=1692&rft_id=info:doi/10.1038%2Fsj.bjc.6690270&rft.externalDBID=NO_FULL_TEXT
thumbnail_l	http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=0007-0920&client=summon
thumbnail_m	http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=0007-0920&client=summon
thumbnail_s	http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=0007-0920&client=summon